Nothing Special   »   [go: up one dir, main page]

HK1222659A1 - 吡咯並 嘧啶衍生物,它們的製備方法和它們作爲激酶抑制劑的用途 - Google Patents

吡咯並 嘧啶衍生物,它們的製備方法和它們作爲激酶抑制劑的用途

Info

Publication number
HK1222659A1
HK1222659A1 HK16110876.0A HK16110876A HK1222659A1 HK 1222659 A1 HK1222659 A1 HK 1222659A1 HK 16110876 A HK16110876 A HK 16110876A HK 1222659 A1 HK1222659 A1 HK 1222659A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
preparation
kinase inhibitors
pyrimidine derivatives
pyrimidine
Prior art date
Application number
HK16110876.0A
Other languages
English (en)
Inventor
‧安吉奧利尼
‧布法
‧梅尼奇恩徹裡
‧摩托
‧波盧奇
‧特拉昆迪
‧祖科托
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Publication of HK1222659A1 publication Critical patent/HK1222659A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16110876.0A 2013-05-14 2016-09-14 吡咯並 嘧啶衍生物,它們的製備方法和它們作爲激酶抑制劑的用途 HK1222659A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13167606 2013-05-14
PCT/EP2014/059342 WO2014184069A1 (en) 2013-05-14 2014-05-07 Pyrrolo[2,3-d]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors

Publications (1)

Publication Number Publication Date
HK1222659A1 true HK1222659A1 (zh) 2017-07-07

Family

ID=48325518

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16110876.0A HK1222659A1 (zh) 2013-05-14 2016-09-14 吡咯並 嘧啶衍生物,它們的製備方法和它們作爲激酶抑制劑的用途

Country Status (7)

Country Link
US (1) US9682083B2 (zh)
EP (1) EP2997030B1 (zh)
JP (1) JP6397897B2 (zh)
CN (1) CN105431436B (zh)
ES (1) ES2646019T3 (zh)
HK (1) HK1222659A1 (zh)
WO (1) WO2014184069A1 (zh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
CN105732614B (zh) * 2014-12-09 2018-06-12 中国科学院广州生物医药与健康研究院 磺酰胺基芳基炔类化合物及其用途
CN105837575B (zh) * 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
CA3003153A1 (en) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP4455145A2 (en) * 2015-12-02 2024-10-30 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
TWI687422B (zh) * 2016-02-23 2020-03-11 日商大鵬藥品工業股份有限公司 新穎稠合嘧啶化合物或其鹽
FI3439663T3 (fi) 2016-04-04 2024-08-28 Loxo Oncology Inc Menetelmiä lasten syöpien hoitamiseksi
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
CA3019671C (en) 2016-04-04 2024-02-20 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
WO2017173604A1 (en) * 2016-04-06 2017-10-12 Hua Medicine (Shanghai) Ltd. Pyrrole derivatives
RS61463B1 (sr) 2016-05-18 2021-03-31 Loxo Oncology Inc Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il) -3-hidroksipirolidin-1-karboksamida
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN108117553B (zh) * 2016-11-30 2019-08-16 暨南大学 炔苯基苯磺酰胺类选择性zak抑制剂及其应用
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) * 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
US11840535B2 (en) 2018-07-02 2023-12-12 Shenzhen Targetrx, Inc. Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
CN109406786B (zh) * 2018-08-29 2021-03-02 郑州工程技术学院 一种检测甲胺磷的免疫层析试纸
CN109085336B (zh) * 2018-08-29 2021-03-02 郑州工程技术学院 一种检测伏马菌素b1的免疫层析试纸
CN108982863B (zh) * 2018-08-29 2021-03-02 郑州工程技术学院 一种检测吡虫啉的免疫层析试纸
CN108776224B (zh) * 2018-08-29 2021-01-01 郑州工程技术学院 一种检测赭曲霉毒素a的免疫层析试纸
CN108896766B (zh) * 2018-08-29 2021-01-01 郑州工程技术学院 一种检测呕吐毒素的免疫层析试纸
CN109061167B (zh) * 2018-08-29 2021-01-01 郑州工程技术学院 一种检测拟除虫菊酯的免疫层析试纸
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3,5-二甲氧基苯基)氨基)喹喔啉衍生物
CN110885307B (zh) * 2019-11-22 2023-03-17 湖北医药学院 环多肽2-苯乙烯基-5-吡咯烷酮-2-酰胺衍生物、制备方法及其应用
US20230101747A1 (en) 2019-12-06 2023-03-30 Schrödinger, Inc. Cyclic compounds and methods of using same
EP4081526A1 (en) 2019-12-27 2022-11-02 Schrödinger, Inc. Cyclic compounds and methods of using same
CN113087709A (zh) * 2020-01-09 2021-07-09 沈阳药科大学 吡咯并嘧啶类衍生物及其制备方法和应用
MX2022013984A (es) 2020-05-08 2023-01-30 Halia Therapeutics Inc Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CN111454261A (zh) * 2020-05-27 2020-07-28 南京普锐达医药科技有限公司 一种4-氯吡咯并嘧啶化合物的合成方法
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
WO2022055963A1 (en) 2020-09-10 2022-03-17 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
JP2024505890A (ja) 2021-01-26 2024-02-08 シュレーディンガー, インコーポレイテッド がん、自己免疫及び炎症性障害の治療に有用な三環式化合物
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
WO2022212326A1 (en) 2021-03-29 2022-10-06 Halia Therapeutics, Inc. Nek7 inhibitors
EP4320127A1 (en) 2021-04-05 2024-02-14 Halia Therapeutics, Inc. Nek7 inhibitors
WO2023169453A1 (zh) * 2022-03-11 2023-09-14 中国科学院上海药物研究所 一类含杂芳环炔基化合物及其制备方法和用途
US20240158394A1 (en) 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
CN115340557A (zh) * 2022-09-19 2022-11-15 安徽大学 一种4-氯-5-碘-7-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法
CN115684424A (zh) * 2022-11-11 2023-02-03 贵州健安德科技有限公司 基于LC-MS/MS检测土壤和水中4-氯-7H-吡咯并[2,3-d]嘧啶的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CA2543116A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. Methods for preparing 7-(2'-substituted-.szlig.-d-ribofuranosyl)-4-(nr2r3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
PE20150637A1 (es) * 2012-10-16 2015-05-08 Almirall Sa Derivados de pirrolotriazinona como inhibidores de pi3k

Also Published As

Publication number Publication date
EP2997030B1 (en) 2017-08-09
CN105431436A (zh) 2016-03-23
WO2014184069A1 (en) 2014-11-20
ES2646019T3 (es) 2017-12-11
JP6397897B2 (ja) 2018-09-26
JP2016518419A (ja) 2016-06-23
CN105431436B (zh) 2017-11-28
US9682083B2 (en) 2017-06-20
EP2997030A1 (en) 2016-03-23
US20160166575A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
HK1222659A1 (zh) 吡咯並 嘧啶衍生物,它們的製備方法和它們作爲激酶抑制劑的用途
HUS2200003I1 (hu) Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
HRP20171724T1 (hr) Imidazo[1,2-b]piridazin derivati kao inhibitori kinaze
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HK1189229A1 (zh) 三環吡咯並衍生物、它們的製備方法和它們作為激酶抑制劑的應用
HK1249759A1 (zh) 取代的嘧啶基和吡啶基吡咯並吡啶酮類、其製備方法及其作為激酶抑制劑的用途
ZA201307839B (en) Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors
HK1255467A1 (zh) 作為雙重dyrk1/clk1抑制劑的新的吡咯並[2,3-d]嘧啶衍生物
AP2013007159A0 (en) Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
IL240877A0 (en) History of triazolo [5,4-d] pyrimidine, their preparation and pharmaceutical preparations containing them
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors
EP2970278A4 (en) Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9-
HK1209740A1 (zh) 二噁烯並-和噁嗪- 嘧啶 抑制劑化合物及使用方法
EP2844660A4 (en) TRIAZOLOPYRIDAZIN COMPOUNDS, USE AS INHIBITORS OF KINASE-LRRK2 AND METHOD FOR THE PRODUCTION THEREOF